Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Umbralisib - TG Therapeutics

Next Previous
X
Search
Drug Profile

Umbralisib - TG Therapeutics

Alternative Names: RP 5307; RP-5264; TGR-1202; UKONIQ

Latest Information Update: 28 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Incozen Therapeutics; Rhizen Pharmaceuticals
  • Developer TG Therapeutics Inc; Vanderbilt-Ingram Cancer Center
  • Class Amines; Antineoplastics; Benzopyrans; Fluorinated hydrocarbons; Ketones; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Casein kinase 1 epsilon inhibitors; Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma; Chronic lymphocytic leukaemia; Marginal zone B-cell lymphoma; Follicular lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic lymphocytic leukaemia
  • Phase II/III Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma
  • Phase II Hodgkin's disease; Waldenstrom's macroglobulinaemia
  • Phase I/II Non-Hodgkin's lymphoma
  • No development reported Multiple sclerosis; Myelofibrosis; Polycythaemia vera; Richter's syndrome; Solid tumours

Most Recent Events

  • 28 Jul 2024 No recent reports of development identified for phase-I development in Polycythaemia-vera(Combination therapy) in USA (PO)
  • 03 Jul 2024 TG Therapeutics terminates phase II trial in Chronic lymphocytic leukaemia (Monotherapy, Second-line therapy or greater) in USA (PO) due to strategic/business decision (NCT02742090)
  • 31 May 2024 TG Therapeutics completes a phase I clinical trials in Polycythaemia vera (Combination therapy) in USA (PO) (NCT02493530)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top